BeneChill Hires CEO

6/7/10

Alan Raffensperger, an Amgen executive director who led the biotech’s nephrology franchise, has been named as the new CEO at San Diego-based BeneChill, according to a report today in Venture Wire. BeneChill, which Xconomy’s Denise Gellene profiled in December, is getting ready to launch its portable RhinoChill device in Europe. The device is used to lower the temperature of the brain and reduce the risk of brain damage, in heart attack patients.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @

By posting a comment, you agree to our terms and conditions.